Search alternatives:
age decrease » a decrease (Expand Search), we decrease (Expand Search), larger decrease (Expand Search)
24 decrease » 026 decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
_ decrease » _ decreased (Expand Search), _ decreasing (Expand Search)
_ 24 » _ 2 (Expand Search), _ 4 (Expand Search)
Showing 1 - 20 results of 6,694 for search '(( third ((age decrease) OR (((mean decrease) OR (_ decrease)))) ) OR ( _ 24 decrease ))', query time: 0.54s Refine Results
  1. 1
    Annual treatment frequencies in all eyes.

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 2
    Annual number of outpatient visits in all eyes.

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups.

    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Annual treatment frequencies in recurrence and non-recurrence groups.

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Factors associated with AL score (multivariable regression analyses for the third follow-up).

    Factors associated with AL score (multivariable regression analyses for the third follow-up). by Eric Priedemann (21175492)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Additional file 7 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 7 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  7. 7
    Additional file 11 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 11 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  8. 8
    Additional file 10 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 10 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  9. 9
    Additional file 3 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study

    Additional file 3 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

    Published 2025
    Save to List
    Saved in:
  10. 10
    Mean 0-30 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI).

    Mean 0-30 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI). by Murat Tutar (22250461)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Mean 0-20 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI).

    Mean 0-20 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI). by Murat Tutar (22250461)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Mean 0-10 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI).

    Mean 0-10 m sprint times for TSG, VBT, and CG groups at pre-test and post-test (with 95% CI). by Murat Tutar (22250461)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    AL scores at baseline and follow-ups.

    AL scores at baseline and follow-ups. by Eric Priedemann (21175492)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescriptions).

    Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  15. 15
    UTI diagnoses by sex and physician specialty (2013–2019).

    UTI diagnoses by sex and physician specialty (2013–2019). by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  16. 16
    Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0).

    Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  17. 17
    Comparison of 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescription.

    Comparison of 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescription. by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  18. 18
    Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n = 269.151prescriptions).

    Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  19. 19
    Shares of specialist groups prescribing 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019.

    Shares of specialist groups prescribing 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:
  20. 20
    Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.814 prescriptions; urologists n = 182.100 prescriptions).

    Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

    Published 2024
    Subjects: “…fluoroquinolone shares decreased…”
    Save to List
    Saved in:

Search Tools: